TABLE 2.

Prevalence of moderate-to-severe VMS amongst women aged 40-65 years^a

	Europeb N = 2,035	US N = 676	Japan N = 760
Estimated prevalence of moderate-to-severe VMS in country/region, %	40c	34	16c
Prevalence by HT group, %d
HT-willinge	24	25	11c
HT-aversef	56	54	79c
HT-contraindicatedg	12	9	8
HT-stoppersh	9	11	5c
HT-cautioni	70	69	52c

HT, hormone therapy; VMS, vasomotor symptoms.

^a Percentages estimated based on respondents’ self-assessment and perceptions.

^b Europe includes France, Germany, Italy, Spain, and UK. Prevalence by individual European country is shown in Supplementary Table 1.

^c Difference statistically significant vs both other regions at 95% CI level.

^d Groups are not mutually exclusive. Self-reported comorbidities do not indicate severity levels, associated treatments, etc.

^e HT-willing: women currently prescribed HT or bioidentical HT or who are willing to take HT.

^f HT-averse: women who are NOT currently treated with hormonal prescription therapies or prescribed bioidentical hormones and who are NOT willing to take HT.

^g HT-contraindicated: women who have been assessed by a physician and HT was deemed not appropriate due to certain conditions/circumstances: bleeding from the genital tract without a determined cause, acute liver failure/active liver disease, deep vein thrombosis, uterine cancer, ovarian cancer, heart attack/stroke/ angina/myocardial infarction (adapted from The North American Menopause Society Position Statement, 2017²¹).

^h HT-stoppers: women who previously received hormonal prescription therapies or prescribed bioidentical “natural” hormones, but are NOT currently on treatment.

ⁱ HT-caution: women with underlying medical conditions (eg, smoking, 1st degree relative with breast cancer, high cholesterol or triglycerides, migraine, diabetes) that warrant a cardiovascular or breast cancer risk assessment before prescribing HT (adapted from Reference 22).